Recordati SpA (MEX:RECN) Moat Score: 6/10 (As of Jun. 25, 2026)


MEX:RECN Recordati SpA MEX:RECN
71 GF Score
Price MXN1,019.79
GF Value MXN1,150.23
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Recordati SpA Moat Score?

Recordati SpA MEX:RECN 71 Moat Score is 6 as of Jun. 25, 2026. GuruFocus rates MEX:RECN with a GF Score™ of 71/100 and a GF Value™ of MXN1,150.23 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 1,033 Drug Manufacturers companies, Recordati SpA ranks better than 97.1% on this metric.

Recordati SpA has the Moat Score of 6, which implies that the company might have Narrow Moat - Strong narrow moat, clearly distinguishable but not wide.

Recordati SpA has Narrow Moat: Recordati SpA has a strong narrow moat due to its valuable pharmaceutical patents and established brand in the healthcare sector. The company benefits from regulatory barriers and a solid distribution network, but its pricing power and innovation are not sufficient for a wide moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Recordati SpA might have Narrow Moat - Strong narrow moat, clearly distinguishable but not wide.

Recordati SpA  (MEX:RECN) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Recordati SpA Moat Score Related Terms

MEX:RECN vs LLY, JNJ, ABBV: Moat Score Comparison

For the Drug Manufacturers - General subindustry, Recordati SpA's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Recordati SpA Moat Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Recordati SpA's Moat Score distribution charts can be found below:

* The bar in red indicates where Recordati SpA's Moat Score falls into.


MEX:RECN
71GF Score
Recordati SpA MEX:RECN
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 6 mean?
Recordati SpA (MEX:RECN) has a Moat Score of 6 as of Jun. 25, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Recordati SpA ranks #30 out of 1033 companies in the Drug Manufacturers industry, placing it in the top 2.9%.
Is Recordati SpA's Moat Score too high?
Recordati SpA's current Moat Score is 6. Based on the distribution chart, Recordati SpA ranks #30 out of 1033 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Recordati SpA has a GF Score™ of 71/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Recordati SpA's Moat Score compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Recordati SpA ranks #30 out of 1033 companies for Moat Score. This places Recordati SpA in the top 3% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Drug Manufacturers company?
A good Moat Score depends on the Drug Manufacturers industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Recordati SpA's current Moat Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Recordati SpA stock overvalued right now?
Based on GuruFocus' analysis, Recordati SpA (MEX:RECN) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN1,150.23, compared to a current price of MXN1,019.79 — trading 11.3% below its estimated fair value. The current Moat Score is 6. Recordati SpA's overall GF Score™ is 71/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Recordati SpA (MEX:RECN), the current Moat Score is 6 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Recordati SpA (MEX:RECN) Overvalued in 2026?

Based on GuruFocus' analysis, Recordati SpA stock appears to be undervalued. The current stock price of MXN1,019.79 is trading 11.3% below its estimated GF Value™ of MXN1,150.23. GuruFocus considers Recordati SpA to be Modestly Undervalued.

Key valuation signals for MEX:RECN:

  • Moat Score: 6
  • GF Value™: MXN1,150.23 vs. price of MXN1,019.79 (11.3% below fair value)
  • GF Score™: 71/100 with 3 warning signs

No single metric tells the full story. See the MEX:RECN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Recordati SpA Business Description

Address Via Matteo Civitali 1, MIlan, ITA, 20148
Recordati SpA is engaged in the development, production, and marketing of pharmaceutical products or of pharmaceutical chemicals. The Company operates in a broad and diverse context, which includes general medicine, specialist medicine, self-medication, and rare diseases. In addition, it is also active in the field of urology, with treatments for benign prostatic hyperplasia and male functional disorders, and in psychiatry. The Company's only operating segment is the Specialty & Primary Care segment. Its geographic areas are Europe, Australasia, America, and Africa.
71GF Score

Get the complete analysis for MEX:RECN

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN1,019.79
Price
MXN1,150.23
GF Value